OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
TPI provides its latest research note on Intuitive Investments Group (IIG.L).
IIG has today been Admitted onto London’s AIM. IIG is an investment group that seeks to leverage the expertise and extensive networks of its Board and Advisory Panel in the
TPI provides its latest research note on Scancell Holdings plc (SCLP.L).
The transformative phase of capital raising that Scancell has undertaken to date in 2020 now appears to have drawn to a close.
Turner Pope Investments is delighted to introduce a forthcoming AIM IPO
Turner Pope Investments (TPI) is delighted to introduce a forthcoming AIM IPO: Intuitive Investments Group plc (“IIG”). The principal behind IIG might not, however, need any introduction as David Evans
OKYO PHARMA LIMITED (OKYO.L) Grant of options – Director dealings
OKYO Pharma Limited (LSE: OKYO) (“OKYO” or the “Company”), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases
OKYO PHARMA LIMITED (OKYO.L) Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
OKYO , the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce
OKYO PHARMA LIMITED (OKYO.L) CLNs to raise £1.4m, intends to list: NASDAQ
Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ
OKYO Pharma LTD (OKYO.L) Issue of convertible loan notes to raise £3,500,000
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
Open Orphan PLC (LON:ORPH) Appointment of Group Chief Financial Officer
Cathal Friel, Executive Chairman of Open Orphan said: “I am delighted that we have appointed Leo as CFO. He has worked with Open Orphan for the past year and is
OptiBiotix Health (AIM:OPTI) Exclusive manufacturing and supply agreement
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a five year agreement